Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) EBIT Margin (2022 - 2025)

Bioregenx (BRGX) has 4 years of EBIT Margin data on record, last reported at 1.67% in Q3 2025.

  • For Q3 2025, EBIT Margin rose 5325.0% year-over-year to 1.67%; the TTM value through Sep 2025 reached 965.35%, down 78323.0%, while the annual FY2024 figure was 972.75%, 87282.0% down from the prior year.
  • EBIT Margin reached 1.67% in Q3 2025 per BRGX's latest filing, up from 24.05% in the prior quarter.
  • Across five years, EBIT Margin topped out at 1.67% in Q3 2025 and bottomed at 66898.48% in Q3 2023.
  • Average EBIT Margin over 4 years is 4840.36%, with a median of 61.69% recorded in 2023.
  • Peak YoY movement for EBIT Margin: plummeted -6687906bps in 2023, then skyrocketed 6684357bps in 2024.
  • A 4-year view of EBIT Margin shows it stood at 62.09% in 2022, then skyrocketed by 50bps to 31.2% in 2023, then plummeted by -12648bps to 3977.69% in 2024, then soared by 100bps to 1.67% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 1.67% in Q3 2025, 24.05% in Q2 2025, and 37.39% in Q1 2025.